

## Supplemental Tables

**Supplementary Table 1.** Total household Income per year (Canadian dollars).

	<b>CATCH (n=2878)</b>	<b>OBRI (n=3734)</b>	<b>RHUMADATA® (n=2890)</b>	<b>Rheum4U (n=709)</b>
≤ \$50,000	611/2878 (21.2%)	< \$20,000 289/3541 (8.2%)	≤ \$19,999 512/2890 (17.7%)	\$5,000 - 30/693 (4.3%)
> \$50,000	956/2878 (33.2%)	\$20,000 - 384/3541 (10.8%)	\$20,000 - \$39,999 565/2890 (19.6%)	\$19,999 - 61/693 (8.8%)
Refuse to answer	858/2878 (29.8%)	\$34,999 - 403/3541 (11.4%)	\$40,000 - \$59,999 360/2890 (12.5%)	\$20,000 - 57/693 (8.2%)
Missing	453/2878 (15.7%)	\$49,999 - 512/3541 (14.5%)	\$60,000 - \$79,999 168/2890 (5.8%)	\$35,999 - 56/693 (8.1%)
		\$74,999 - 1016/3541 (28.7%)	\$80,000 - \$99,999 77/2890 (2.7%)	\$52,000 - 56/693 (8.1%)
		≥ \$75,000 495/3541 (14.0%)	≥ \$100,000 101/2890 (3.5%)	\$66,999 - 41/693 (5.9%)
		Refuse to answer 442/3541 (12.5%)	Missing 1107/2890 (38.3%)	\$81,999 - 44/693 (6.3%)
				\$111,999 - 39/693 (5.6%)
				\$112,000 - 27/693 (3.9%)
				\$127,999 - 27/693 (3.9%)
				\$128,000 - 14/693 (2.0%)
				143,999 - 57/693 (8.2%)
				\$144,000 - 184/693 (26.6%)
				\$159,999 - 14/693 (2.0%)
				\$160,000 - 57/693 (8.2%)
				\$175,999 - 184/693 (26.6%)
				≥ \$176,000 184/693 (26.6%)
				Refuse to answer 184/693 (26.6%)

“Refuse to answer” was denoted as a specific survey question option some cohorts. Missingness of any response (where found) is also reported.

**Supplementary Table 2.** Treatment patterns for moderate-high disease activity\*.

	<b>CATCH</b>	<b>OBRI</b>	<b>RHUMADATA®</b>	<b>Rheum4U</b>
Initial DMARD therapy	N= 1306	N = 454	N = 399	N = 55
Monotherapy	763/1306 (58%)	260/454 (57%)	170/399 (43%)	18/55 (33%)
Methotrexate	527/1306 (40%)	184/454 (41%)	118/399 (30%)	10/55 (18%)
SC	270/527 (51%)	35/184 (19%)	9/118 (8%)	4/10 (40%)
Oral	257/527 (49%)	149/184 (81%)	109/118 (92%)	6/10 (60%)
Hydroxychloroquine (HCQ)	212/1306 (16%)	50/454 (11%)	51/399 (13%)	7/55 (13%)
Other DMARD mono	24/1306 (2%)	26/454 (6%)	1/399 (<1%)	1/55 (2%)
Sulfasalazine (SSZ)	Not available	23/454 (5%)	1/399 (<1%)	1/55 (2%)
Leflunomide (LEF)	Not available	3/454 (1%)	0/399 (0%)	0/55 (0%)
Dual therapy	451/1306 (35%)	147/454 (32%)	226/399 (57%)	31/55 (56%)
MTX + HCQ	398/1306 (31%)	95/454 (21%)	217/399 (54%)	26/55 (47%)
MTX + SSZ	11/1306 (1%)	17/454 (4%)	1/399 (<1%)	1/55 (2%)
MTX + LEF	22/1306 (2%)	2/454 (0%)	1/399 (<1%)	1/55 (2%)
Other DMARD Dual Therapy	20/1306 (2%)	33/454 (7%)	7/399 (2%)	3/55 (5%)
Triple therapy	82/1306 (6%)	47/454 (10%)	3/399 (1%)	4/55 (7%)
MTX + HCQ + SSZ	82/1306 (6%)	33/454 (7%)	2/399 (1%)	2/55 (4%)
Other DMARD Triple Therapy	0/1306 (0%)	14/454 (3%)	1/399 (<1%)	2/55 (4%)
bDMARD or tsDMARD	10/1306 (1%)	Not available	0/399 (0%)	2/55 (4%)
Anti-TNF +/- csDMARD	7/1306 (1%)	Not available	0/399 (0%)	1/55 (2%)
Non-TNF +/- csDMARD	3/1306 (0%)	Not available	0/399 (0%)	1/55 (2%)

Biologic Disease Modifying anti-Rheumatic Drugs (bDMARD); Conventional Synthetic Disease Modifying anti-Rheumatic Drugs (csDMARD); Targeted Synthetic Disease Modifying anti-Rheumatic Drugs (tsDMARD)

\* based on a Disease Activity Score- 28 (DAS28) score of >3.2 or Clinical Disease Activity Index (CDAI) score of >10

**Supplementary Table 3.** DMARD therapies that patients must fail to meet provincial insurance program eligibility criteria for biologic or targeted synthetic DMARDs.

	AB	BC	MB	NB	NL	NS	ON	PEI	QC	SK	YT
<b>Monotherapy</b>											
Any 3 DMARDs			X								
MTX (oral or parenteral)			O				X		X	X	
MTX (parenteral)	X	X		X	X	X		X			X
LFD	X	O	O				O			X	O
Sulfasalazine											O
Azathioprine											O
Any DMARD except MTX									O	X	
<b>Dual Therapy</b>											
Any DMARD combination			X			X	O		O		X
MTX + any DMARD	X			I	I			I			
MTX + LFD		O					O				
<b>Triple Therapy</b>											
MTX + any 2 DMARDs				X	X	X		X			
MTX + LFD + HCQ		O					O				

Canadian Provinces and Territories: Alberta (AB), British Columbia (BC), Manitoba (MB), New Brunswick (NB), Newfoundland and Labrador (NL), Nova Scotia (NS), Ontario (ON), Prince Edward Island (PEI), Quebec (QC), Saskatchewan (SK), Yukon (YT). Northwest Territories and Nunavut have been omitted from the table as data was not available

Notes: X = mandatory criteria; O = one of multiple options to meet criteria; I = mandatory where patient cannot take triple therapy